Migraine Two-Hour Pain Response Efficacy Standard Suggested By Committee
Executive Summary
A two-hour pain-free response endpoint should be the primary measure of efficacy for migraine drugs, members of FDA's Peripheral & Central Nervous System Drugs Advisory Committee suggested Aug. 4
You may also be interested in...
FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says
FDA Needs To Put Meaning Behind “Clinically Meaningful,” Lipicky Says
FDA's increasing requirements for clinical meaningfulness in efficacy measures make it more difficult to predict the agency's regulatory actions, former division director Ray Lipicky says
Unresolved Review Issues: Clinical Trials Are Easier Fix Than Safety, Efficacy
Problems with clinical trial design and/or execution identified pre-submission are the issues most likely to be resolved in advance of first FDA action, Booz Allen Hamilton's first-cycle review report finds